[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339847-105":59,"doc-detail-339847-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-impact-of-the-expression-level-of-growth-differentiation-factor-15-in-tumor-tissue-on-the-response-to-immunotherapy-in-non-small-cell-lung-cancer","The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer","","Growth differentiation factor-15 (GDF-15) is overexpressed across multiple cancers and supports immune evasion by suppressing T-cell activation. Building on phase 2a findings from GDFATHER-TRIAL combining the GDF-15 neutralizing antibody visugromab (CTL002) with nivolumab, this study investigated whether GDF-15 expression in non-small cell lung cancer (NSCLC) tumor tissues predicts immunotherapy response. Retrospective evaluation of GDF-15 levels and survival outcomes assessed prognostic significance for nivolumab-treated metastatic patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-impact-of-the-expression-level-of-growth-differentiation-factor-15-in-tumor-tissue-on-the-response-to-immunotherapy-in-non-small-cell-lung-cancer/339847/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-impact-of-the-expression-level-of-growth-differentiation-factor-15-in-tumor-tissue-on-the-response-to-immunotherapy-in-non-small-cell-lung-cancer/339847.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does GDF-15 do in the cancer immune environment?","Question",{"text":112,"@type":113},"GDF-15 is overexpressed in many cancers and inhibits T-cell activation, contributing to immune evasion by tumor cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was GDF-15 expression measured and grouped in the study?",{"text":117,"@type":113},"GDF-15 expression was assessed by immunochemistry staining and categorized by staining intensity into low (scores 0–1) and high (scores 2–3) groups.",{"name":119,"@type":110,"acceptedAnswer":120},"Which survival and response outcomes were compared between GDF-15 groups?",{"text":121,"@type":113},"The study compared progression-free survival (PFS), overall survival (OS), and objective response rates, with high GDF-15 linked to worse PFS/OS and lower response.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339847,1791074205,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Akdogan etal. BMC Cancer (2024) 24:954 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12727-3](https://doi.org/10.1186/s12885-024-12727-3)  \nRESEARCH Open Access  \nThe impact of the expression level of growth  differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer  \nOrhun Akdogan 1*, Betul Ogut2, Osman Sutcuoglu 1, Aysenur Sert2, Fatih Gurler 1, Nalan Akyurek2, Nuriye Ozdemir 1, Ahmet Ozet 1 and Ozan Yazici 1  \nAbstract  \nBackground Growth differentiation factor-15 (GDF-15), a member oftheTGF-β superfamily, is overexpressed in various cancers and facilitates immune evasion by inhibiting T-cell activation. GDFATHER-TRIAL’s phase 2a results demonstrated promising outcomes when combining the GDF-15 neutralizing antibody visugromab (CTL002) with nivol umab, enhancing the response to immunotherapy. This study evaluated the prognostic significance of GDF-15 expression in non-small cell lung cancer (NSCLC) tumor tissues in terms of immunotherapy response.  \nMethods This retrospective study included 50 patients with metastatic NSCLC treated with nivol umab at Gazi University Hospital between January 2021 and July 2023. GDF-15 expression was evaluated using immunochemistry staining and categorized based on the intensity of cytoplasmic or membranous staining. Samples were divided into a low expression group (scores 0 and 1) and a high expression group (scores 2 and 3) . The primary outcomes were progression-free survival (PFS) and overall survival (OS), which were analyzed using Kaplan‒Meier and Cox proportional hazards models. Objective response rates were assessed in secondary outcomes.  \nResults Of the 50 patients, 43 were men (86%), with a median age of 63.9 years. Half of the patients exhibited low GDF-15 expression. High GDF-15 expression correlated with shorter PFS and OS. The median PFS was 7.8 months for the low-expression group versus 4.4 months for the high-expression group (HR, 0 .41; 95% CI, 0 .20–0. 83; p = 0 . 013) . The median OS was 18.1 months for the low-expression group compared to 11.8 months for the high-expression group (HR, 0 . 36; 95% CI, 0 .16–0. 78; p = 0 . 007) . The objective response rate was significantly greater in the low GDF-15 group (52%) than in the high GDF-15 group (24%) (p = 0 . 040) .  \nConclusion Elevated GDF-15 expression in NSCLC tumor tissues is associated with poorer response to nivol umab, suggesting that GDF-15 is a potential prognostic biomarker for immunotherapy efficacy. These findings warrant further validation through prospective studies to optimize treatment strategies for NSCLC patients.  \nKeywords GDF-15, Immunotherapy, NSCLC, Biomarker, Chemotherapy  \n*Correspondence:  \nOrhun Akdogan[orhunakdogan@gmail.com](orhunakdogan@gmail.com)  \n1Faculty of Medicine, Department of Medical Oncology, Gazi University, Ankara, Turkey  \n2Faculty of Medicine, Department of Pathology, Gazi University, Ankara, Turkey  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](crea","cbCaitO7vmau48QH","https://ap.wps.com/l/cbCaitO7vmau48QH","pdf",2186127,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What does GDF-15 do in the cancer immune environment?\",\"answer\":\"GDF-15 is overexpressed in many cancers and inhibits T-cell activation, contributing to immune evasion by tumor cells.\"},{\"question\":\"How was GDF-15 expression measured and grouped in the study?\",\"answer\":\"GDF-15 expression was assessed by immunochemistry staining and categorized by staining intensity into low (scores 0–1) and high (scores 2–3) groups.\"},{\"question\":\"Which survival and response outcomes were compared between GDF-15 groups?\",\"answer\":\"The study compared progression-free survival (PFS), overall survival (OS), and objective response rates, with high GDF-15 linked to worse PFS/OS and lower response.\"}]","The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer | PDF",1790032618,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d52a61bcdadf7f320d7abce49c6a010.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd3373ed66bc1f10a0e7f22774cf25e1.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c6a55450ad1dddfa18dc66da29a8b3c.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dcd3f04eb984a6d9879e9c220fa44969.webp",980,1306]